Reuters - Video

Edition: US | UK | IN | CN | JP

video Business

Breakingviews TV: Botox Tuesday

Tuesday, June 25, 2019 - 03:21

AbbVie is buying Allergan, maker of Botox, for $63 billion – a 45% premium. It’s a great deal for the seller’s shareholders, but not much more than an overpriced superficial filler for the buyer. Robert Cyran explains the wrinkles in the merger.

▲ Hide Transcript

View Transcript

AbbVie is buying Allergan, maker of Botox, for $63 billion – a 45% premium. It’s a great deal for the seller’s shareholders, but not much more than an overpriced superficial filler for the buyer. Robert Cyran explains the wrinkles in the merger.

Press CTRL+C (Windows), CMD+C (Mac), or long-press the URL below on your mobile device to copy the code

Breakingviews TV: Botox Tuesday

Tuesday, June 25, 2019 - 03:21